Literature DB >> 18647858

Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.

Verawan Uchaipichat1, Aleksandra Galetin, J Brian Houston, Peter I Mackenzie, J Andrew Williams, John O Miners.   

Abstract

Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. 4MU and 1NP glucuronidation by UGT2B7 exhibit sigmoidal kinetics characteristic of homotropic cooperativity (autoactivation), which may be modeled assuming the existence of two equivalent, interacting substrate binding sites. In contrast, UGT2B7-catalyzed AZT glucuronidation follows hyperbolic (Michaelis-Menten) kinetics. Although 4MU and 1NP decreased the binding affinity of AZT, the kinetics of AZT glucuronidation changed from hyperbolic to sigmoidal in the presence of both modifiers. Data were well described by a generic two-substrate binding site model in which there is no interaction between the sites in the absence of 4MU or 1NP, but heterotropic cooperativity results from the binding of modifier. Inhibition of 4MU and 1NP glucuronidation by AZT and interactions between 4MU and 1NP required more complex three-site models, where the modifier acts via a distinct effector site to alter either substrate binding affinity or Vmax without affecting the homotropic cooperativity characteristic of 4MU and 1NP glucuronidation. It is noteworthy that 1NP inhibited 4MU glucuronidation, whereas 4MU activated 1NP glucuronidation. The results are consistent with the existence of two "catalytic" sites for each substrate within the UGT2B7 active site, along with multiple effector sites. The multiplicity of binding and effector sites results in complex kinetic interactions between UGT2B7 substrates, which potentially complicates inhibition screening studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647858     DOI: 10.1124/mol.108.048645

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

2.  Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2010-10-28       Impact factor: 3.922

3.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

4.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

5.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

6.  Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases.

Authors:  Krishna C Chimalakonda; Stacie M Bratton; Vi-Huyen Le; Kan Hui Yiew; Anna Dineva; Cindy L Moran; Laura P James; Jeffery H Moran; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2011-07-11       Impact factor: 3.922

7.  Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

8.  Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3.

Authors:  Nina Sneitz; Michael H Court; Xiuling Zhang; Kaisa Laajanen; Karen K Yee; Pamela Dalton; Xinxin Ding; Moshe Finel
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

9.  Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.

Authors:  Anne-Sophie Bélanger; Patrick Caron; Mario Harvey; Peter A Zimmerman; Rajeev K Mehlotra; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-06-01       Impact factor: 3.922

10.  Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.

Authors:  Kristine C Olson; Ryan W Dellinger; Qing Zhong; Dongxiao Sun; Shantu Amin; Thomas E Spratt; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2009-07-09       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.